An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension-Reference-Cited by-同舟云学术

An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension

Published:2012-10 Issue:1 Volume:64 Page:95-103
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Owen Keith,Cross David M.,Derzi Mazin,Horsley Elizabeth,Stavros Fiona L.

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference33 articles.

1. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension;Abman;Annu. Rev. Med.,2009

2. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study;Barst;Chest.,2002

3. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics;Carducci;J. Clin. Oncol.,2002

4. Endothelin receptor antagonists in pulmonary arterial hypertension;Dupuis;Eur. Respir. J.,2008

5. European Medicines Agency. 2007. Thelin scientific discussion: European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000679/WC500037904.pdf. Accessed January 30, 2012.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐267;Biopharmaceutics & Drug Disposition;2024-01-18

2. Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery;Drug Discovery Today;2023-07

3. Predicting toxicity from chemical structure of a drug compound;Essentials of Pharmatoxicology in Drug Research, Volume 1;2023

4. Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis;Frontiers in Cardiovascular Medicine;2022-08-02

5. Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension;International Journal of Pharmaceutics;2022-06